Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:17:49 18/07/2024 BST			5-day change	1st Jan Change
6,031 ^JPY	-0.69%		+0.07%	+55.76%

07-16	Daiichi Sankyo's Disposes Shares as Restricted Compensation	MT
07-10	Daiichi Sankyo Opens New Affiliate for Oncology in Greece	CI

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

January 31, 2024 at 04:00 am

Daiichi Sankyo Company, Limited revised dividend guidance for the year ending March 31, 2024. For the year, the company now expects dividend of JPY 30.00 per share against JPY 15.00 per share paid a year ago.

Latest news about Daiichi Sankyo Co., Ltd.

Daiichi Sankyo's Disposes Shares as Restricted Compensation	07-16	MT
Daiichi Sankyo Opens New Affiliate for Oncology in Greece	07-10	CI
Financials lift Japanese shares on rate-hike speculation	07-02	RE
Daiichi Sankyo Buys Back 13.5 Billion Yen Worth of Shares in June	07-02	MT
Sanofi eyes German insulin investment of up to $1.6 bln, source says	07-01	RE
Daiichi Sankyo Buys Back Shares	07-01	MT
Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2024.	07-01	CI
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC	06-27	DJ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27	RE
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	06-27	CI
Health Care Down as Moderna Slides -- Health Care Roundup	06-26	DJ
AstraZeneca Signs Mobile Support Collaboration for Breast Cancer Patients	06-19	MT
Daiichi Sankyo to Dispose of 320 Million Yen Worth of Shares as Restricted Shares Remuneration	06-18	MT
Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May	06-04	MT
Transcript : Daiichi Sankyo Company, Limited - Special Call	06-04
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%	06-03	MT
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug	06-03	MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results	06-02	RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels	06-02	RE
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified	06-02	RE
Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial	06-02	CI
AstraZeneca and Daiichi Sankyo Announce Positive Results from the DESTINY-Breast06 Phase III Trial Showed That ENHERTU Metastatic Breast Cancer and the Overall Trial Population	06-02	CI
RevolKa Signs Master Service Agreement with Daiichi Sankyo	05-28	CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	05-27	DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	05-27	MT

Chart Daiichi Sankyo Co., Ltd.

Duration

Period

More charts

Company Profile

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6,073 JPY

Average target price

6,306 JPY

Spread / Average Target

+3.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+55.76%	72.39B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

EPS Revisions